OnabotulinumtoxinA Reduces Nocturnal Voids and Improves Quality of Life in Overactive Bladder Patients with Nocturia

Dmochowski R1, Ginsberg D2, Parsons M3, Robinson D4, Magyar A5, Nicandro J6, Drake M7

Research Type

Clinical

Abstract Category

Nocturia

Abstract 165
Updates on the Use of Botulinum Toxin
Scientific Podium Short Oral Session 10
Wednesday 7th October 2015
14:15 - 14:22
210AE
Overactive Bladder Detrusor Overactivity Quality of Life (QoL)
1. Vanderbilt University Medical Center, Nashville, TN, USA, 2. USC Institute of Urology, Los Angeles, CA, USA, 3. Birmingham Women's NHS Foundation, Edgbaston, Birmingham, UK, 4. King's College Hospital NHS Foundation, London, UK, 5. Allergan, Inc, Bridgewater, NJ, USA, 6. Allergan, Inc, Irvine, CA, USA, 7. Bristol Urological Institute, Bristol, UK
Presenter
R

Roger Dmochowski

Links

Abstract